Daina Graybosch
Stock Analyst at Leerink Partners
(0.09)
# 4,645
Out of 4,693 analysts
498
Total ratings
38.9%
Success rate
-7.4%
Average return
Main Sectors:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPHA Innate Pharma | Upgraded: Buy | $2 → $4 | $2.18 | +83.49% | 33 | Aug 11, 2026 | |
| REPL Replimune Group | Upgraded: Buy | $17 | $15.93 | +6.72% | 2 | Aug 3, 2026 | |
| GILD Gilead Sciences | Downgraded: Hold | $129 → $127 | $149.77 | -15.20% | 29 | Jul 20, 2026 | |
| CGEN Compugen | Maintained: Buy | $13 → $5 | $2.61 | +91.57% | 28 | May 21, 2026 | |
| RCUS Arcus Biosciences | Maintained: Buy | $49 → $47 | $29.69 | +58.30% | 25 | Apr 20, 2026 | |
| BNTX BioNTech SE | Downgraded: Hold | $107 → $113 | $103.93 | +8.73% | 67 | Feb 2, 2026 | |
| MRK Merck & Co. | Maintained: Buy | $107 → $114 | $150.73 | -24.37% | 77 | Dec 15, 2025 | |
| IPSC Century Therapeutics | Downgraded: Hold | $7 → $2 | $2.07 | -3.38% | 26 | Nov 17, 2025 | |
| SMMT Summit Therapeutics | Maintained: Sell | n/a | $14.20 | - | 7 | Oct 22, 2025 | |
| NBP NovaBridge Biosciences | Initiated Coverage: Buy | $9 | $1.77 | +408.47% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $2.43 | +188.07% | 37 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $6 | $4.03 | +48.82% | 21 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $10 | $0.9761 | +924.49% | 20 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $9.11 | n/a | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.73 | n/a | 20 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.62 | n/a | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $0.39 | $0.000001 | n/a | 32 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6 | $4.13 | n/a | 19 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $75.65 | n/a | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $72.01 | n/a | 26 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $5.53 | n/a | 1 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.0001 | n/a | 10 | Apr 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $1.8 | $5.78 | n/a | 8 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 35.00 | CHF 3.33 | n/a | 1 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €82.06 → €86.38 | €140.05 | n/a | 3 | Aug 25, 2020 |
Innate Pharma
Aug 11, 2026
Upgraded: Buy
Price Target: $2 → $4
Current: $2.18
Upside: +83.49%
Replimune Group
Aug 3, 2026
Upgraded: Buy
Price Target: $17
Current: $15.93
Upside: +6.72%
Gilead Sciences
Jul 20, 2026
Downgraded: Hold
Price Target: $129 → $127
Current: $149.77
Upside: -15.20%
Compugen
May 21, 2026
Maintained: Buy
Price Target: $13 → $5
Current: $2.61
Upside: +91.57%
Arcus Biosciences
Apr 20, 2026
Maintained: Buy
Price Target: $49 → $47
Current: $29.69
Upside: +58.30%
BioNTech SE
Feb 2, 2026
Downgraded: Hold
Price Target: $107 → $113
Current: $103.93
Upside: +8.73%
Merck & Co.
Dec 15, 2025
Maintained: Buy
Price Target: $107 → $114
Current: $150.73
Upside: -24.37%
Century Therapeutics
Nov 17, 2025
Downgraded: Hold
Price Target: $7 → $2
Current: $2.07
Upside: -3.38%
Summit Therapeutics
Oct 22, 2025
Maintained: Sell
Price Target: n/a
Current: $14.20
Upside: -
NovaBridge Biosciences
Oct 6, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $1.77
Upside: +408.47%
Sep 4, 2025
Maintained: Buy
Price Target: $12 → $7
Current: $2.43
Upside: +188.07%
Sep 4, 2025
Maintained: Hold
Price Target: $20 → $6
Current: $4.03
Upside: +48.82%
Sep 4, 2025
Reiterated: Buy
Price Target: $12 → $10
Current: $0.9761
Upside: +924.49%
Aug 15, 2025
Reiterated: Buy
Price Target: $28
Current: $9.11
Upside: n/a
Aug 13, 2025
Maintained: Buy
Price Target: $8
Current: $2.73
Upside: n/a
Aug 13, 2025
Reiterated: Buy
Price Target: $7
Current: $3.62
Upside: n/a
May 14, 2025
Downgraded: Hold
Price Target: $5 → $0.39
Current: $0.000001
Upside: n/a
Aug 28, 2024
Maintained: Hold
Price Target: $6
Current: $4.13
Upside: n/a
Dec 11, 2023
Maintained: Buy
Price Target: n/a
Current: $75.65
Upside: n/a
Sep 15, 2023
Maintained: Hold
Price Target: $1.5
Current: $72.01
Upside: n/a
Jun 5, 2023
Maintained: Buy
Price Target: n/a
Current: $5.53
Upside: n/a
Apr 27, 2022
Maintained: Buy
Price Target: $5
Current: $0.0001
Upside: n/a
Apr 1, 2022
Downgraded: Hold
Price Target: $25 → $1.8
Current: $5.78
Upside: n/a
Apr 6, 2021
Maintained: Buy
Price Target: CHF 35.00
Current: CHF 3.33
Upside: n/a
Aug 25, 2020
Maintained: Buy
Price Target: €82.06 → €86.38
Current: €140.05
Upside: n/a